Dow Up0.51% Nasdaq Up0.24%

Response Genetics, Inc (RGDX)

0.55 Up 0.03(5.77%) Nov 21, 4:00PM EST
ProfileGet Profile for:
Response Genetics, Inc
1640 Marengo Street
6th Floor
Los Angeles, CA 90033
United States - Map
Phone: 323-224-3900
Fax: 323-224-3096

Index Membership:N/A
Industry:Medical Laboratories & Research
Full Time Employees:109

Business Summary 

Response Genetics, Inc., a life science company, is engaged in the research, development, marketing, and sale of pharmacogenomic tests for use in the treatment of cancer primarily in the United States, Asia, and Europe. It develops genetic tests that measure predictive factors for therapy response in tumor tissue samples. The company offers tests for non-small cell lung cancer, gastric and gastroesophageal cancer, melanoma and thyroid cancer, and breast cancer patientsÂ’ tumor tissue specimens through its ResponseDX: Lung, ResponseDX: Colon, ResponseDX: Gastric, ResponseDX: Melanoma, ResponseDX: Thyroid, ResponseDX: Breast, and ResponseDX: and Tissue of Origin test suites. It also provides HER2 mutation detection, cKIT mutation detection, MET gene amplification, and UGT1A1 SNP tests, including ROS1 FISH, ROS1 RT-PCR, c-MET, HER2 FISH, and VEGFR2. In addition, the company focuses on the development of various diagnostic tests for predicting therapy response and determining the diagnosis and prognosis of solid tumors in cancer patients. It serves community based oncologists, pathologists, physician offices, and hospitals, as well as pharmaceutical companies and cancer care centers through its sales force. The company was formerly known as Bio Type, Inc. and changed its name to Response Genetics, Inc. in August 2000. Response Genetics, Inc. was founded in 1999 and is headquartered in Los Angeles, California.

Key Statistics

Company Websites 
Home Page
Search Yahoo! for:
More on Response Genetics, Inc

Key Executives 
Mr. Thomas A. Bologna , 66
Chairman and Chief Exec. Officer
Mr. Kevin R. Harris CPA, 45
Chief Financial Officer, Principal Accounting Officer and VP
Dr. Stephanie H. Astrow Ph.D., MBA, 52
VP of R&D
Mr. Adanech Getachew , 37
Gen. Counsel
Mr. Alan Cheeks M.A,
VP of Laboratory Operations
Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in USD.
View Insiders